BRPI0517843A - compostos de moléculas conjugadas com a atividade de absorção de células aumentada - Google Patents

compostos de moléculas conjugadas com a atividade de absorção de células aumentada

Info

Publication number
BRPI0517843A
BRPI0517843A BRPI0517843-6A BRPI0517843A BRPI0517843A BR PI0517843 A BRPI0517843 A BR PI0517843A BR PI0517843 A BRPI0517843 A BR PI0517843A BR PI0517843 A BRPI0517843 A BR PI0517843A
Authority
BR
Brazil
Prior art keywords
molecule
compounds
increased cell
absorption activity
cell absorption
Prior art date
Application number
BRPI0517843-6A
Other languages
English (en)
Inventor
Christophe Bonny
Didier Coquoz
Jianhua Chen
Original Assignee
Xigen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xigen Sa filed Critical Xigen Sa
Publication of BRPI0517843A publication Critical patent/BRPI0517843A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSTOS DE MOLéCULAS CONJUGADAS COM A ATIVIDADE DE ABSORçãO DE CéLULAS AUMENTADA. A presente invenção refere-se a uma molécula conjugada compreendendo pelo menos uma primeira porção (1) compreendendo uma sequência carreadora e pelo menos uma segunda porção (II) compreendendo pelo menos uma molécula de fármaco antitumor ou uma molécula de inibidor protease, a dita molécula conjugada compreendendo aminoácidos Denantioméricos em sua porção (1). Além disso, a invenção refere-se a composições farmacêuticas contendo a dita molécula conjugada bem como ao uso da dita molécula conjugada para tratamento terapêutico. Também são descritos métodos para melhorar a permeabilidade da célula ou solubilidade em água.
BRPI0517843-6A 2004-11-12 2005-11-09 compostos de moléculas conjugadas com a atividade de absorção de células aumentada BRPI0517843A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04026934A EP1656951A1 (en) 2004-11-12 2004-11-12 Conjugates with enhanced cell uptake activity
PCT/EP2005/011991 WO2006050930A2 (en) 2004-11-12 2005-11-09 Conjugates with enhanced cell uptake activity

Publications (1)

Publication Number Publication Date
BRPI0517843A true BRPI0517843A (pt) 2008-10-21

Family

ID=34927367

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517843-6A BRPI0517843A (pt) 2004-11-12 2005-11-09 compostos de moléculas conjugadas com a atividade de absorção de células aumentada

Country Status (10)

Country Link
EP (2) EP1656951A1 (pt)
JP (1) JP2008519785A (pt)
CN (1) CN101072589A (pt)
AR (1) AR051765A1 (pt)
AU (1) AU2005303949A1 (pt)
BR (1) BRPI0517843A (pt)
CA (1) CA2585421A1 (pt)
EA (1) EA200700976A1 (pt)
IL (1) IL182760A0 (pt)
WO (1) WO2006050930A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
JP2010514779A (ja) * 2006-12-29 2010-05-06 ルバンス セラピュティックス インク． 逆配列ｈｉｖ−ｔａｔポリペプチドを用いる輸送分子
EP2178549B1 (en) * 2007-07-26 2016-09-14 Revance Therapeutics, Inc. Antimicrobial peptide and compositions thereof
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) * 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
US8895497B2 (en) 2009-12-04 2014-11-25 Dcb-Usa, Llc Cathepsin S inhibitors
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
CN104884078B (zh) * 2012-10-17 2017-06-20 诺和诺德股份有限公司 用于口服肽递送的脂肪酸酰化d‑氨基酸
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
CN105307670A (zh) 2013-06-26 2016-02-03 埃克西金炎症有限公司 Jnk信号转导途径的细胞渗透肽抑制剂用于治疗多种疾病的新用途
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
EP3758730B1 (en) * 2018-02-27 2022-11-02 Lipotrue, S.L. Peptides and compositions for use in cosmetics and medicine
CN108794581B (zh) * 2018-06-26 2021-09-10 江苏大学 一种靶向结合淋巴癌细胞系的特异性d型多肽及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040152084A1 (en) * 2003-01-31 2004-08-05 Slattum Paul M. Compounds and processes for single-pot attachment of a label to nucleic acid
IL132941A0 (en) * 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
EP2269654A3 (en) * 1999-08-24 2011-04-13 Cellgate Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US20030108539A1 (en) * 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6610820B1 (en) * 1999-10-12 2003-08-26 University Of Lausanne Cell-permeable peptide inhibitors of the JNK signal transduction pathway
AU2002240312A1 (en) * 2001-02-08 2002-08-19 Pankaj Paranjp Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
WO2004092339A2 (en) * 2003-04-11 2004-10-28 Ilex Products, Inc. Modulation of muc1 mediated signal transduction
ES2351976T3 (es) * 2003-04-29 2011-02-14 Avi Biopharma, Inc. Composiciones para mejorar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células.

Also Published As

Publication number Publication date
EP1656951A1 (en) 2006-05-17
AR051765A1 (es) 2007-02-07
AU2005303949A1 (en) 2006-05-18
CN101072589A (zh) 2007-11-14
WO2006050930A2 (en) 2006-05-18
EA200700976A1 (ru) 2007-12-28
IL182760A0 (en) 2007-07-24
WO2006050930A3 (en) 2007-04-26
CA2585421A1 (en) 2006-05-18
EP1809334A2 (en) 2007-07-25
JP2008519785A (ja) 2008-06-12

Similar Documents

Publication Publication Date Title
BRPI0517843A (pt) compostos de moléculas conjugadas com a atividade de absorção de células aumentada
CY1109722T1 (el) Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole
BRPI0510273A (pt) derivados de tetraazabenzo[e]azuleno e análogos destes
ATE524476T1 (de) Pyrazolopyrimidine als modulatoren von caseinkinase ii (ck2)
DK1521593T3 (da) Transdermale botulinumtoksinforbindelser
IL169896A0 (en) Methods and compositions for administering therapeutic and diagnostic agents
BRPI0613005A8 (pt) uso de polipeptídeos de aprotinina como veículos em conjugados farmacêuticos.
BR0312408A (pt) Inibidores de peptìdeo de ligação de proteìna smac a inibidor de apoptose de proteìnas (iap)
GT200500237A (es) Derivados de pirimidina
BRPI0414000B8 (pt) composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica
NZ543467A (en) The severe acute respiratory syndrome coronavirus
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
MX2007005644A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de cinasa.
BRPI0517458A (pt) derivados da xantina com atividade para o receptor hm74a
WO2009088838A3 (en) Triarylmethane analogs and their use in treating cancers
BR0305628A (pt) Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso
Werle et al. Evaluation and improvement of the properties of the novel cystine-knot microprotein McoEeTI for oral administration
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
AU2001264515A1 (en) Melphalan derivatives and their use as cancer chemotherapeutic drugs
BRPI0720230B8 (pt) formulação nutricional oralmente administrável, uso da formulação, e, composição
TW200727903A (en) Stable pharmaceutical compositions of 5, 10 methylenetetrahydrofolate
Hur et al. Effect of oligoarginine conjugation on the antiwrinkle activity and transdermal delivery of GHK peptide
Suzuki et al. Anthraquinone derivatives as a new family of protein photocleavers
WO2007056263A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
Park et al. Effect of the oligo (ethylene glycol) group on the antioxidant activity of manganese salen complexes

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.

B15K Others concerning applications: alteration of classification

Ipc: C07K 7/06 (2006.01), A61K 47/64 (2017.01), C07K 5/